Janssen Report MAA Submission of Amivantamab to EMA for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Shots:
- The EMA Submission is based on P-l CHRYSALIS study to evaluate the safety and efficacy of Amivantamab as a monotherapy and in combination with Lazertinib in adult patients for the treatment of advanced NSCLC
- Result of CHRYSALIS Study assessed efficacy using overall response rate per Response Evaluation Criteria- CBR- DOR and PFS as well as the safety profile of amivantamab
- Amivantamab is an investigational- fully – human EGFR-MET bispecific antibody with immune cell – directing activity that targets tumours with activating and resistance EGFR mutations and MET mutations and amplifications
Ref: Janssen | Image: Janssen
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com